 |
Atheromed
Atheromed is an early stage company developing a novel atherectomy device for the treatment of occlusive peripheral arterial disease, which can lead to claudication and critical limb ischemia. |
Note |
The Vertical Group participated in a Series B financing that was led by US Venture Partners. Tony Chou is a member of the board of directors, and Lucas Buchanan serves as a board observer. |
| |
|
| |
Biosurface
Technologies Inc. (BioSET)
BioSET is a development stage medical technology company
engaged in the development of
synthetic growth factors which mimic the effect of naturally
occurring growth factors, but which are much less expensive to
produce and easier to incorporate into coatings for medical
devices. The Company currently is conducting clinical evaluations
of a BMP-2 mimetic (B2A) product for both spine and ankle fusions.
BioSET also has a collaboration with Tornier to develop its
FGF-2 mimetic (F2A) agent for orthopedic soft tissue repair. |
| Note |
The Vertical Group was a founding investor
of BioSET.
John E. Runnells is a member of its Board of Directors. |
| |
|
| |
ENTrigue
Surgical
ENTrigue Surgical is an early commercial stage company that is
developing several product platforms for the relatively
underserved Ears, Nose, & Throat market. The company was
founded in 2007 by an ENT surgeon (Dr. Donald Gonzales) and
a proven medical device industry executive (Fred Dinger).
Among ENTrigue's first commercialized products are a line of
articulating instruments; a septal stapling system utilizing
resorbable staples; an implantable device to prevent displacement
of the turbinate during sinus surgery; and a proprietary balloon
dilation system for the treatment of sinusitis. |
| Note |
The Vertical Group was a founding investor
in ENTrigue, and Richard Emmitt is a member of its Board of Directors. |
| |
|
| |
Flexuspine
Flexuspine is an early stage company that is developing novel devices
for the treatment of degenerative spine disease. The founders are
experienced executives, engineers, and surgeons with extensive experience
in the development of spinal technologies. Flexuspine initiated a clinical trial for its FSU
(Functional Spinal Unit) in 2010. |
| Note |
The Vertical Group participated in the
Series B financing with Onset Ventures and Warburg Pincus. John
E. Runnells is a member of the Board of Directors. |
| |
|
| |
Galil
Medical
Galil Medical is a pioneer and leader in the market for cryotherapy
systems utilized to treat prostate and kidney cancer as well as
non-cancerous disorders such as uterine fibroids. The company's
technology is based on the ability to freeze and ablate tissue in
a procedure that is both precise and minimally invasive. Based in
Yokneam, Israel, Galil has a direct sales organization in the United
States and has world-wide sales exceeding $20 million.
|
| Note |
The Vertical Group participated in a change of control
and recapitalization financing for Galil Medical. Richard B. Emmitt
is a member of its Board of Directors. |
| |
|
 |
Home Dialysis Plus
Home Dialysis Plus (or HD+) is an early-stage company developing a novel, portable home hemodialysis system for patients in kidney failure. The system is intended to allow patients to experience the benefits of gentler, more frequent dialysis, a treatment regime that more closely simulates natural kidney processes and has been shown to improve patients’ quality of life. |
Note |
The Vertical Group participated in a Series A financing that was led by Warburg Pincus. Tony Chou is a member of the board of directors, and David DeGiralamo serves as a board observer. |
| |
|
| |
Incumed
Incumed is a medical device "incubator" committed to working
with physicians, engineers, and other inventors with new product
ideas that may not have the commercial profile required by large
corporations or the venture capital community. Incumed partners
with inventors and utilizes its experience and resources to maximize
the commercial value of a new product idea. |
| Note |
The Vertical Group was Incumed's founding investor.
Richard B. Emmitt and John E. Runnells are members of its Board
of Directors. |
| |
|
| |
InPhenix
Corporation
InPhenix is a leading developer and manufacturer of optoelectronic
devices for the medical, defense, and telecom markets. The Company's
Super Light Emitting Diodes (SLEDs) are utilized in a variety of
optical imaging systems for biomedical applications, and its customers
include several leading manufacturers of ophthalmic and laboratory
diagnostic instrumentation. |
| Note |
The Vertical Group was an early investor
in InPhenix. Yue-Teh Jang is a member of its Board of Directors. |
| |
|
 |
Omada Health is a pioneer of digital health, and builds evidence-based programs for chronic disease prevention and health promotion. The company's flagship product, Prevent , is a 16-week program for individuals at risk for diabetes and is based entirely on the landmark Diabetes Prevention Program (DPP) clinical trial. The Omada Health founding team is an interdisciplinary group of technologists and entrepreneurs from Google, Amazon, IDEO, Stanford, and Harvard who are passionate about creating accessible technology to prevent disease. |
| Note |
The Vertical Group was an early investor in InPhenix. Tony Chou is a member of its Board of Directors. |
| |
|
| |
Oncomed
Pharmaceuticals, Inc
OncoMed is an early stage biopharmaceutical company that is
developing drugs based on the newly discovered concept of
'cancer stem cells'. The company's scientific founders were
among those responsible for first isolating such cancer stem cells, which appear
to be the rare cells in tumors responsible for
producing malignancy and tumor growth. In 2007 OncoMed and GlaxoSmithKline (“GSK”)
formed a strategic alliance to develop cancer therapeutics based on the Company's
cancer stem cell antibody technology. In 2010, Oncomed
completed a second major collaboration partnership with Bayer
Pharmaceuticals for development of antibodies in the Wnt
pathway. The company retains rights to many additional drug
development candidates and has the capital in place to finance
the completion of
thirteen major phase ll clinical trials by the end of 2016. |
| Note |
The Vertical Group participated in the
founding venture round.
Jack W. Lasersohn is a member of its Board of Directors |
| |
|
| |
PhotoThera
Inc.
PhotoThera is a development stage company that is exploring
non-invasive therapeutic applications for laser light. In 2008
PhotoThera completed a large randomized trial for its new
therapy for stroke. While demonstrating a positive treatment
effect, the clinical results did not reach the study’s statistical
objective. Nevertheless, based on the trial’s observed positive
treatment effect, as well as the positive results of previous
clinical trials, PhotoThera recently has initiated a new clinical
trial and remains optimistic about the potential of its technology. |
| Note |
The Vertical Group participated in an early
financing for PhotoThera. Jack W. Lasersohn is a member of its Board
of Directors. |
| |
|
|
|
ProteinSimple (formally
Cell Biosciences)
Cell Biosciences is an early stage company developing research tools for
the biotechnology industry. The company has developed a novel instrument
system that will improve both the throughput and accuracy of traditional
protein detection assays currently performed using the 'western blot' system.
The company is also ‘rolling up’smaller instrumentation companies
in this space and has already completed a number of substantial acquisitions.
A number of the acquired and internally developed technologies have the
potential for breakout growth. We expect the company to exit 2012 with
sales exceeding $40 million and break even EBITDA in 2011.
|
|
Note
|
The Vertical Group participated in a Series A financing.
Jack W. Lasersohn is The Vertical Group contact. |
| |
|
| |
Proteolix,
Inc.
Proteolix is an biopharamaceutical company that is developing drugs which target the activities of the proteosome. The founders are among the world’s leading experts on the proteosome and their previous work led directly to the development of Velcade, the leading FDA approved drug for the treatment for multiple myeloma. The Proteolix drug, Carfilzomib, has completed several Phase II clinical trials that demonstrate efficacy equivalent or superior to Velcade without the latter drug’s dose limiting toxicity. These clinical results also suggest that the Proteolix drug may have superior efficacy compared to Celgene’s Revlimid, with a similar toxicity profile. In early testing, Carfilzomib also has demonstrated efficacy against both renal cell and small cell lung cancer. Proteolix was acquired by Onyx Pharmaceuticals in 2009 for total consideration which may exceed $800 million. |
| Note |
The Vertical Group participated in the founding round of venture financing. Jack W. Lasersohn was a member of its Board of Directors. |
| |
|
 |
Silk Road Medical
Silk Road Medical is an early stage company developing a novel endovascular approach to treating neurovascular disease. |
Note |
The Vertical Group incubated Silk Road Medical and remains its sole investor. |
| |
|
| |
Tepha,
Inc.
Tepha is a development stage medical device company engaged
in utilizing unique and proprietary biomaterials derived from a
class of polymers known as PHAs (polyhydroxyalkanoates).
Relative to conventional medical grade polymers, the Tepha
PHA-derived materials are distinguished by their elasticity,
flexibility, and non-acidic, "cell friendly" biodegradation. This
profile positions the TephaFLEX and TephELAST polymers as
ideal materials for medical devices of the future, and especially
those devices emerging from the rapidly expanding field of tissue
engineering. Tepha received its first FDA 510(k) release for a
PHA polymer derived device in 2007. The company's
commercial partners include Aesculap, ENTrigue Surgical, Lifecell, NMT Medical, Tornier, and a NYSE-listed leader in the hernia repair market. |
| Note |
The Vertical Group was the lead investor
in Tepha at the time of its spin-off from its sister company, Metabolix,
Inc. Richard B. Emmitt and Edward M. Giles are members of Tepha's
Board of Directors. |
| |
|
| |
TetraLogic
Pharmaceuticals
TetraLogic Pharmaceuticals discovers and develops important drugs to treat cancer. TetraLogic's founding scientists, Drs. George McLendon and Yigong Shi, at Princeton University, developed TetraLogic's core technology, called 'Smac mimetics', which enables drugs to be developed that unblock the cell death or apoptosis pathway, resulting in the death of tumor cells. The company initiated clinical studies during 2010 with very promising early results. The company also completed a major Series C equity financing led by new investor Clarus Venture Partners. |
| Note |
The Vertical Group participated in the company's Series B financing in 2006 and Series C financing in 2010. Jack Lasersohn was a member of its Board of Directors from 2006-2010 and became a board observer in 2010 following the Series C financing. |
| |
|
| |
Tornier
Tornier is a global orthopedic company and a leader in the market
for shoulder and extremity joint replacement systems. Based in Grenoble,
France, Tornier has been a respected orthopedic industry pioneer
since its founding during the 1940's. During the 1990's, Tornier's
close collaboration with prominent surgeons led to the commercialization
of the AEQUALIS shoulder and SALTO ankle product lines. During 2007
and 2008, Tornier completed four acquisitions and four corporate
partnerships to expand its line of upper and lower extremity product
lines and also to enter the sports/arthroscopy market. The
Company's annual sales are approximately $200 million. |
| Note |
In July of 2006 The Vertical Group and its
co-investor, Warburg Pincus, purchased a controlling interest in Tornier.
Richard Emmitt is a member of its Board of Directors. |
| |
|
|
ViaCyte
ViaCyte is a pioneer in the field of islet cell transplantation
for the treatment of diabetes. The company's cellular encapsulation
and cell culture technology may lead to an alternative to life-long
insulin injection therapy for millions of diabetics. ViaCyte has
strategic partnerships with Becton Dickenson and SurModics. |
Note |
The Vertical Group participated in the founding financing
round for the Company. Jack W. Lasersohn is the Vertical Group contact. |